Glyxambi is a prescription medication used to treat Type 2 Diabetes.
It is a single product containing 2 medications: empagliflozin and linagliptin. Empagliflozin belongs to a group of drugs called sodium-glucose co-transporter-2 inhibitors. It works by stopping the reabsorption of glucose by the kidney, increasing glucose excretion from the body, and lowering blood sugar levels. Linagliptin belongs to a group of drugs called DPP-4 inhibitors. These work by increasing the amount of insulin made by the body after meals, and by decreasing the amount of glucose produced by the liver.
This medication comes in tablet form and is taken typically once a day in the morning, with or without food. Common side effects of Glyxambi include urinary tract infections, stuffy or runny nose and sore throat, and upper respiratory tract infections.